Abstract
This paper examines the safety and efficacy of budesonide, an inhaled corticosteroid, as both an early and late-stage treatment for COVID-19. Drawing on a comprehensive review of global research, including the U.K. STOIC and PRINCIPLE trials, the Brazil TOGETHER trial, and additional studies from Saudi Arabia, Australia, and India, we provide robust evidence supporting budesonide's therapeutic potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
